Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization
Peijia Medical's TaurusOne® Transcatheter Aortic Valve Replacement System Approved for Commercialization News provided by Share this article Share this article SUZHOU, China, April 24, 2021 /PRNewswire/ -- A new interventional solution from China for structural heart disease is about to be launched onto the market. Recently, TaurusOne ® Transcatheter Aortic Valve Replacement System (hereinafter referred to as "TaurusOne ®") developed by Peijia Medical (Suzhou) Co., Ltd., located in Suzhou Industrial Park, Jiangsu Province, was officially approved for commercialization by the National Medic...